HDAC9 and neoplasm: These findings prompted us to investigate the role of the class IIa HDAC inhibitor CHDI0039 together with cisplatin or bortezomib as novel treatment combinations, particularly for platinum-resistant HNSCC, as has been suggested for other tumor entities [9,10,21].